what is glp-1 agonist A Closer Look at the Dermatological Profile of Agonists Hype Or Hope? Latest Research
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Morieri ML, Frison V, Rigato M, et al
Efficacy and Safety of Efpeglenatide in Patients with Type 2 Diabetes and Obesity: a Systematic Review
doi: 10.1001/jamapsychiatry.2024.4789
Exposure was defined through prescriptions rather than confirmed adherence
The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study
